Skip to main content
. 2022 Jul 1;132(13):e145099. doi: 10.1172/JCI145099

Figure 6. RBM10 transfection recovers the Bcl-xS to Bcl-xL ratio and the apoptotic response to EGFR TKI therapy.

Figure 6

(A) qRT-PCR and (B) conventional RT-PCR analysis of the Bcl-xS to Bcl-xL ratio (mRNA levels) following genetic reconstitution of RBM10 or Bcl-xS in RBM10-deficient A014 cells. (C) A014 cells (RBM10-deficient) overexpressing Bcl-xS or reconstituted with RBM10 24 hours before treatment with osimertinib (500 nM) or the DMSO control for 48 hours. Cell lysates were harvested, and the indicated proteins were measured by Western blotting. (D) Caspase 3/-7 activity was measured with the Caspase-Glo 3/7 assay. Each bar represents the mean ± SEM of the FC after normalization to the DMSO control. Data represent 3 independent experiments. *P < 0.05, by 1-way ANOVA.